Brumm Joshua T — SEC insider filings
SEC reporting owner CIK 1528826. 26 insider filings on record with FilingPulse; latest filed 2026-09-18.
Transaction summary — filings shown
Covers all 26 filings on record, filed 2020-09-18 to 2026-09-18. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): 34 legs across 15 filings — 1,444,939 shares, $27,600,156 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 53.
- Largest priced transaction: sale of 202,238 shares @ $25.30 ($5,116,621) in Dyne Therapeutics, Inc., filed 2024-03-12.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | CEO & President, Director | 22 | — | 31 legs · 1,393,187 sh · $26,679,313 | 49 |
| CRESCENT BIOPHARMA, INC. (CBIO) | Chief Executive Officer, Director | 4 | — | 3 legs · 51,752 sh · $920,842 | 4 |
Insider filings — Brumm Joshua T
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-18 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) | Sale (S): 1,610 @ $17.90 · Sale (S): 7,837 @ $16.71 | EDGAR |
| 2026-06-23 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) | Sale (S): 42,305 @ $17.99 | EDGAR |
| 2025-12-17 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) | Grant/award (A): 45,117 · Grant/award (A): 10,000 · Grant/award (A): 180,467 (derivative) @ $0 | EDGAR |
| 2025-12-10 | 4 | CRESCENT BIOPHARMA, INC. (CBIO) | Grant/award (A): 345,672 (derivative) @ $0 | EDGAR |
| 2024-03-12 | 4 | Dyne Therapeutics, Inc. (DYN) | Option exercise (M): 153,931 @ $5.54 · Option exercise (M): 209,412 @ $5.54 · Sale (S): 202,238 @ $25.30 · Sale (S): 160,670 @ $26.72 · Sale (S): 435 @ $27.38 · Option exercise (M): 50,000 @ $5.54 · +7 more | EDGAR |
| 2024-03-11 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 9,086 @ $25.85 | EDGAR |
| 2024-03-01 | 4 | Dyne Therapeutics, Inc. (DYN) | Option exercise (M): 5,520 @ $5.54 · Sale (S): 5,520 @ $27.50 · Option exercise (M): 94,480 @ $5.54 · Sale (S): 18,976 @ $28.25 · Sale (S): 74,090 @ $29.23 · Sale (S): 1,414 @ $29.70 · +3 more | EDGAR |
| 2024-01-31 | 4 | Dyne Therapeutics, Inc. (DYN) | Gift (G): 20,000 @ $0 · Gift (G): 1,500 @ $0 | EDGAR |
| 2024-01-04 | 4 | Dyne Therapeutics, Inc. (DYN) | Option exercise (M): 51,183 @ $1.03 · Sale (S): 15,382 @ $18.34 · Sale (S): 19,775 @ $19.03 · Sale (S): 16,026 @ $20.50 · Option exercise (M): 18,536 @ $1.03 · Option exercise (M): 200,000 @ $5.54 · +5 more | EDGAR |
| 2023-12-12 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 7,585 @ $10.72 | EDGAR |
| 2023-11-16 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 358,877 @ $0 · Grant/award (A): 139,750 (derivative) @ $0 | EDGAR |
| 2023-09-20 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 12,032 @ $9.41 | EDGAR |
| 2023-09-13 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 7,672 @ $10.41 | EDGAR |
| 2023-06-12 | 4 | Dyne Therapeutics, Inc. (DYN) | Gift (G): 20,000 @ $0 · Gift (G): 1,800 @ $0 · Option exercise (M): 30,088 @ $1.03 · Sale (S): 46,811 @ $13.15 · Sale (S): 14,189 @ $13.47 · Option exercise (M): 76,582 @ $1.03 · +6 more | EDGAR |
| 2023-03-15 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 7,318 @ $13.33 | EDGAR |
| 2022-12-13 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 144,000 @ $0 · Sale (S): 3,322 @ $10.87 · Grant/award (A): 222,000 (derivative) @ $0 | EDGAR |
| 2022-10-11 | 4 | Dyne Therapeutics, Inc. (DYN) | Option exercise (M): 14,200 @ $1.03 · Sale (S): 14,200 @ $13.37 · Option exercise (M): 195,800 @ $1.03 · Sale (S): 195,800 @ $12.46 · Gift (G): 13,000 @ $0 · Gift (G): 2,500 @ $0 · +2 more | EDGAR |
| 2022-09-21 | 4 | Dyne Therapeutics, Inc. (DYN) | Disposition to issuer (D): 11,836 @ $13.70 | EDGAR |
| 2022-09-15 | 4 | Dyne Therapeutics, Inc. (DYN) | Disposition to issuer (D): 3,480 @ $14.05 | EDGAR |
| 2022-07-06 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 24,118 @ $0 · Disposition to issuer (D): 10,963 @ $8.24 · Grant/award (A): 153,931 (derivative) @ $0 · Grant/award (A): 78,386 (derivative) @ $0 | EDGAR |
| 2022-06-15 | 4 | Dyne Therapeutics, Inc. (DYN) | Disposition to issuer (D): 3,540 @ $4.95 | EDGAR |
| 2022-03-14 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 3,384 @ $8.73 | EDGAR |
| 2021-12-14 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 118,190 @ $0 · Grant/award (A): 177,285 (derivative) @ $0 | EDGAR |
| 2021-10-04 | 4 | Dyne Therapeutics, Inc. (DYN) | Gift (G): 3,500 @ $0 | EDGAR |
| 2021-09-22 | 4 | Dyne Therapeutics, Inc. (DYN) | Sale (S): 3,425 @ $15.61 · Sale (S): 4,584 @ $16.11 | EDGAR |
| 2020-09-18 | 4 | Dyne Therapeutics, Inc. (DYN) | Grant/award (A): 107,027 @ $0 · Grant/award (A): 320,781 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-09-16 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1528826 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs